<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>circRNA-miRNA Regulatory Inversion Theory - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Theory Details for theory-11</h1>

        <div class="section">
            <h2>Theory (General Information)</h2>
            <div class="info-section">
                <p><strong>ID:</strong> theory-11</p>
                <p><strong>Name:</strong> circRNA-miRNA Regulatory Inversion Theory</p>
                <p><strong>Type:</strong> specific</p>
                <p><strong>Theory Query:</strong> Build a theory of why the propensity to get certain cancers is inversely correlated with neurodegenerative disease, based on the following results.</p>
                <p><strong>Description:</strong> Circular RNAs (circRNAs) acting as microRNA sponges show systematic inverse expression patterns between Alzheimer's disease and multiple cancers, creating opposing post-transcriptional regulatory landscapes. Specifically, 12 of 13 shared circRNAs between AD cortical tissue and cancer datasets exhibit inverse expression (upregulated in one disease, downregulated in the other), with particularly strong inverse correlations observed in acute myeloid leukemia, juvenile myelomonocytic leukemia, renal cell carcinoma, and myelofibrosis. Hub circRNAs (circPICALM, circRTN4, circMAN2A1) identified through network centrality analysis regulate miRNA availability for targeting shared mRNA networks enriched in IL-12/IL-23 inflammatory signaling and viral response pathways, which have opposing effects in neurodegeneration (promoting Aβ pathology) versus cancer (supporting anti-tumor immunity). This mechanism provides a specific epigenetic layer explaining inverse comorbidity through competitive endogenous RNA (ceRNA) networks.</p>
                <p><strong>Knowledge Cutoff Year:</strong> 2029</p>
                <p><strong>Knowledge Cutoff Month:</strong> 12</p>
                <p><strong>Base Model:</strong> claude-sonnet-4-5-20250929</p>
            </div>
        </div>
        </div>

        <div class="section">
            <h2>Theory (Statement/Laws)</h2>

            <h3>Theory Statements/Laws</h3>
            <hr/>
            <h3>Statement 0: circRNA Expression Inversion Principle</h3>
            <p><strong>Statement:</strong> Circular RNAs show systematic inverse expression between AD cortical tissue and multiple cancer types: 12 of 13 shared circRNAs exhibit opposite expression patterns (upregulated in one disease and downregulated in the other), with negative Spearman correlations ranging from r=-0.30 to r=-0.58 depending on cancer type and AD staging. The inverse pattern is reproducible across independent cohorts (Knight ADRC and MSBB for AD; MiOncoCirc database for cancers) and is strongest when correlating with AD Braak staging rather than binary disease status.</p>
            <p><strong>Domain/Scope:</strong> Applies to AD cortical tissue (Knight ADRC and MSBB cohorts analyzed) and cancers with circRNA profiling in MiOncoCirc database (28 cancer types tested). Strongest inverse correlations observed in hematologic malignancies (AML Spearman r=-0.33, p=0.0038; JMML r=-0.52, p=0.002) and renal cell carcinoma (r=-0.34, p=0.0026). Does not apply to temporal lobe epilepsy (two independent TLE datasets showed no correlation), indicating specificity to protein aggregation neurodegenerative diseases. Analysis used DESeq2 for differential expression with circRNAs present in ≥50% of datasets retained.</p>
            <h4>Special Cases</h4>
            <ol>
                <li>One circRNA (hsa-miR-29c) was downregulated in both GBM and AD, representing the single exception to inverse pattern among 13 shared circRNAs</li>
                <li>Temporal lobe epilepsy circRNA signatures showed no correlation with cancer in two independent datasets, demonstrating specificity not to all brain diseases but to neurodegenerative processes</li>
                <li>Correlation magnitudes vary significantly by cancer type: hematologic malignancies and renal cell carcinoma show strongest inverse patterns (r < -0.3), while some cancers show weaker or non-significant correlations</li>
                <li>Braak staging correlations (e.g., Knight ADRC r=-0.52 for JMML, r=-0.46 for renal cell carcinoma) are consistently stronger than binary disease status correlations, indicating disease stage dependency</li>
                <li>CDR (Clinical Dementia Rating) associations also show inverse patterns but with different magnitude than Braak staging, suggesting multiple aspects of AD progression relate to circRNA changes</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>Computational differential expression analysis of AD cortical RNA-seq from two cohorts (Knight ADRC and MSBB) and MiOncoCirc cancer circRNA database identified 35 concordant GBM circRNAs, 7 AD circRNAs, and 13 shared circRNAs; 12 of 13 showed inverse expression patterns <a href="../results/extraction-result-34.html#e34.0" class="evidence-link">[e34.0]</a> </li>
    <li>Spearman correlations between AD-associated circRNAs and cancer circRNA expression: AML Knight ADRC r=-0.33 (p=0.0038), MSBB r=-0.34 (p=0.003); renal cell carcinoma Knight ADRC r=-0.34 (p=0.0026), MSBB r=-0.30 (p=0.009) <a href="../results/extraction-result-34.html#e34.0" class="evidence-link">[e34.0]</a> </li>
    <li>Braak staging showed stronger correlations: AML Braak vs Knight ADRC r=-0.52 (p=0.002), MSBB r=-0.58 (p=0.0004); renal cell carcinoma Braak r=-0.46 (p=0.007), r=-0.55 (p=0.001) <a href="../results/extraction-result-34.html#e34.0" class="evidence-link">[e34.0]</a> </li>
    <li>Multiple additional cancer types showed significant negative correlations including JMML, myelofibrosis, ALL, bladder cancer, cholangiocarcinoma, colorectal, esophageal adenocarcinoma, HNSCC, hepatocellular carcinoma, lung adenocarcinoma, NHL, pancreatic, ovarian, stomach, and thyroid cancers <a href="../results/extraction-result-34.html#e34.0" class="evidence-link">[e34.0]</a> </li>
    <li>Temporal lobe epilepsy served as negative control: two independent TLE datasets showed no associations with cancer circRNA patterns, arguing against generic brain-disease artifact and supporting specificity to neurodegenerative processes <a href="../results/extraction-result-34.html#e34.0" class="evidence-link">[e34.0]</a> </li>
    <li>Parallel analysis of miRNAs in GBM versus AD found 13 shared miRNAs with 12 showing inverse patterns, targeting genes like MAPK1, IGF1R, CALM family members, PI3K and CDK/E2F families, providing mechanistic parallel at miRNA level <a href="../results/extraction-result-29.html#e29.0" class="evidence-link">[e29.0]</a> </li>
    <li>Network centrality analysis identified circPICALM, circRTN4, and circMAN2A1 as hub circRNAs with highest network centrality scores, suggesting master regulator roles in the inverse regulatory networks <a href="../results/extraction-result-34.html#e34.0" class="evidence-link">[e34.0]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> <span style="color: green; font-weight: bold;">new</span></p>
        <p><strong>Explanation:</strong> While circRNA sponge biology is established and some miRNA inverse patterns have been noted, the systematic class-level inverse expression pattern with statistical quantification, multi-cancer validation, disease-stage correlations, and hub identification represents fundamentally new findings from Zhang et al. (2021) that were not known prior to this work.</p>            <p><strong>What Already Exists:</strong> Individual circRNAs have been studied in cancer or AD separately, and circRNA functions as miRNA sponges are well-established. Some individual miRNAs have been noted to show inverse expression between diseases.</p>            <p><strong>What is Novel:</strong> This is the first systematic, genome-wide demonstration that circRNAs as a class show inverse expression patterns between AD and multiple cancer types, with quantified Spearman correlations across 28 cancer types and reproducibility across independent AD cohorts. The identification of specific hub circRNAs (circPICALM, circRTN4, circMAN2A1) through network analysis as potential master regulators is entirely novel.</p>
        <p><strong>References:</strong> <ul>
    <li>Zhang et al. (2021) Revisiting the Relationship Between Alzheimer's Disease and Cancer With a circRNA Perspective [Original systematic study reporting this finding]</li>
    <li>Hansen et al. (2013) Natural RNA circles function as efficient microRNA sponges [Foundational circRNA sponge mechanism]</li>
    <li>Memczak et al. (2013) Circular RNAs are a large class of animal RNAs with regulatory potency [circRNA function and abundance]</li>
    <li>Candido et al. (2019) The analysis of miRNA expression profiling datasets reveals inverse microRNA patterns in glioblastoma and Alzheimer's disease [Prior miRNA inverse pattern work]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 1: Hub circRNA-Mediated Network Regulation Principle</h3>
            <p><strong>Statement:</strong> Three circRNAs (circPICALM, circRTN4, circMAN2A1) function as hub regulators in circRNA-miRNA-mRNA networks, as determined by network centrality analysis. These hub circRNAs act as competing endogenous RNAs (ceRNAs) that sequester multiple miRNAs (identified through ENCORI CLIP-seq data with >1 experiment threshold), thereby modulating the availability of these miRNAs to regulate downstream mRNA targets. The resulting networks are enriched for genes involved in shared biological processes that have opposing consequences in AD versus cancer.</p>
            <p><strong>Domain/Scope:</strong> Network construction based on ENCORI CLIP-seq-derived interactions between 17 AD/cancer-associated circRNAs and their miRNA and mRNA targets, using CLIP evidence threshold >1 experiment. Hub identification via STRING protein-protein interaction network and centrality analysis. Applicable to understanding regulatory architecture but requires experimental validation of predicted interactions in relevant cell types (neurons vs. cancer cells).</p>
            <h4>Special Cases</h4>
            <ol>
                <li>circPICALM has been functionally validated in bladder cancer (Yan et al. 2019), providing experimental support for at least one hub's oncogenic role</li>
                <li>MAN2A1 (parental gene of circMAN2A1) has validated roles in both N-glycan maturation affecting immune response and tumor cell sensitivity to T-cell killing, providing dual disease relevance</li>
                <li>Network predictions require cell-type-specific validation as miRNA-mRNA interactions can be tissue-dependent</li>
                <li>CLIP-seq threshold of >1 experiment balances sensitivity and specificity but may miss some true interactions or include false positives</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>Network construction using ENCORI CLIP-seq-derived miRNA-circRNA and miRNA-mRNA interactions (CLIP evidence >1) produced a circRNA-miRNA-mRNA network for 17 circRNAs; network centrality analysis identified circPICALM, circRTN4, and circMAN2A1 as hubs with highest centrality scores <a href="../results/extraction-result-34.html#e34.0" class="evidence-link">[e34.0]</a> </li>
    <li>Network target genes include HNRNPA2B1, SOD1, B2M, RPL27, EIF3D, PDCD6IP, MIF, NUP93, CDC42, and MAN2A1 (parental gene of circMAN2A1), spanning diverse cellular functions relevant to both diseases <a href="../results/extraction-result-34.html#e34.0" class="evidence-link">[e34.0]</a> </li>
    <li>Functional validation exists for circPICALM: Yan et al. (2019) demonstrated circPICALM functions in bladder cancer, confirming at least one hub's cancer relevance <a href="../results/extraction-result-34.html#e34.0" class="evidence-link">[e34.0]</a> </li>
    <li>MAN2A1 inhibition sensitizes tumor cells to T-cell killing and synergizes with anti-PD-L1 therapy (Shi et al. 2020), providing experimental link between circMAN2A1 parental gene and cancer immunotherapy <a href="../results/extraction-result-34.html#e34.0" class="evidence-link">[e34.0]</a> </li>
    <li>GO/KEGG enrichment of network target genes identified IL-12 signaling, viral processes, and immune response pathways as top enriched categories, providing biological coherence to the network <a href="../results/extraction-result-34.html#e34.0" class="evidence-link">[e34.0]</a> </li>
    <li>Parallel miRNA network analysis in GBM vs AD identified MAPK1 as key signaling node targeted oppositely by miR-106a, miR-424, and miR-330, demonstrating similar hub-based regulatory architecture at miRNA level <a href="../results/extraction-result-29.html#e29.0" class="evidence-link">[e29.0]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> <span style="color: green; font-weight: bold;">new</span></p>
        <p><strong>Explanation:</strong> While the computational methods are established, their application to identify specific circRNA hubs mediating inverse disease comorbidity represents a novel finding. The specific hub circRNAs and their connection to mechanistically relevant pathways were not known prior to this work.</p>            <p><strong>What Already Exists:</strong> circRNA-miRNA-mRNA network construction methods are established. Individual circRNAs like circPICALM have been studied. Network centrality analysis is a standard approach. ceRNA hypothesis is well-known.</p>            <p><strong>What is Novel:</strong> The identification of these three specific circRNAs as hubs in the AD-cancer inverse relationship is novel. The demonstration that these hubs link to pathways with validated opposing disease effects (IL-12/IL-23 in AD vs. cancer) is new. The application of network analysis to explain inverse comorbidity through ceRNA mechanisms is a novel conceptual advance.</p>
        <p><strong>References:</strong> <ul>
    <li>Zhang et al. (2021) Revisiting the Relationship Between Alzheimer's Disease and Cancer With a circRNA Perspective [Original hub identification]</li>
    <li>Salmena et al. (2011) A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? [ceRNA concept foundation]</li>
    <li>Yan et al. (2019) circPICALM functional study in bladder cancer [Experimental validation of one hub]</li>
    <li>Shi et al. (2020) MAN2A1 inhibition sensitizes tumor cells [MAN2A1 validation]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 2: IL-12/IL-23 Inflammatory Axis Inverse Regulation Law</h3>
            <p><strong>Statement:</strong> circRNA-miRNA-mRNA networks identified through GO/KEGG enrichment are significantly enriched for IL-12 family cytokine signaling (IL-12, IL-23, IL-27, IL-35) and viral response pathways. Activation of IL-12/IL-23 signaling promotes Aβ accumulation and AD pathology (genetic/pharmacological inhibition of IL-12/IL-23 reduced cerebral Aβ in APP/PS1 mice), while in cancers IL-12 mediates anti-tumor immunity through IFN-γ production and T-cell activation. The inverse regulation of circRNAs that modulate miRNAs targeting IL-12/IL-23 pathway components creates opposing inflammatory states that differentially affect disease progression.</p>
            <p><strong>Domain/Scope:</strong> Applies to IL-12/IL-23-mediated inflammation in AD pathogenesis (validated in APP/PS1 mouse model) and cancer immunology (particularly immune-responsive tumor types). Most relevant to inflammatory/immune-mediated aspects of disease rather than all pathogenic mechanisms. MAN2A1-related effects on N-glycan maturation and immune recognition provide mechanistic link to PD-L1-based immunotherapy.</p>
            <h4>Special Cases</h4>
            <ol>
                <li>IL-12 clinical trials in cancer have largely failed to produce durable anti-tumor responses and showed significant toxicity, indicating complex biology not captured by simple activation/inhibition models</li>
                <li>IL-12/IL-23 inhibition reduced Aβ in APP/PS1 mice but human translation remains unvalidated; pathway effects may differ between mouse models and human AD</li>
                <li>MAN2A1 effects are specifically linked to N-glycan maturation affecting immune recognition, representing a subset of IL-12/IL-23 pathway biology</li>
                <li>Viral response pathway enrichment suggests infection/inflammation triggers may be particularly relevant contexts for circRNA-mediated regulation</li>
                <li>The balance between pro-inflammatory (pathogenic in AD) and anti-tumor (protective in cancer) effects may depend on tissue context, immune cell composition, and disease stage</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>DIANA-mirPath pathway prediction and GO/KEGG enrichment identified IL-12 family signaling and viral response/infection pathways as top enriched categories in circRNA-miRNA-mRNA networks constructed from 17 circRNAs <a href="../results/extraction-result-34.html#e34.0" class="evidence-link">[e34.0]</a> </li>
    <li>Vom Berg et al. (2012) experimental validation: genetic and pharmacological inhibition of IL-12/IL-23 signaling reduced cerebral Aβ in APP/PS1 transgenic mouse model of AD, demonstrating IL-12/IL-23 promotes AD pathology <a href="../results/extraction-result-34.html#e34.0" class="evidence-link">[e34.0]</a> </li>
    <li>IL-12 mediates anti-tumor immunity in cancers through induction of IFN-γ production by T cells and NK cells, but clinical trials have shown limited efficacy and toxicity issues, indicating complexity <a href="../results/extraction-result-34.html#e34.0" class="evidence-link">[e34.0]</a> </li>
    <li>circMAN2A1 identified as hub; MAN2A1 parental gene encodes enzyme involved in N-glycan maturation that modulates immune response and tumor cell susceptibility to T-cell killing <a href="../results/extraction-result-34.html#e34.0" class="evidence-link">[e34.0]</a> </li>
    <li>Shi et al. (2020) demonstrated MAN2A1 inhibition sensitizes tumor cells to T-cell killing and synergizes with anti-PD-L1 immunotherapy, providing therapeutic validation of MAN2A1 pathway in cancer immunity <a href="../results/extraction-result-34.html#e34.0" class="evidence-link">[e34.0]</a> </li>
    <li>STRING GO enrichment showed network target genes participate in IL-12 signaling, viral processes, and immune response, with statistical significance indicating non-random pathway convergence <a href="../results/extraction-result-34.html#e34.0" class="evidence-link">[e34.0]</a> </li>
    <li>Herpes simplex infection pathway enrichment suggests viral/infection-triggered inflammatory responses may be particularly relevant contexts for the circRNA-IL-12/IL-23 regulatory axis <a href="../results/extraction-result-34.html#e34.0" class="evidence-link">[e34.0]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> <span style="color: orange; font-weight: bold;">somewhat-related-to-existing</span></p>
        <p><strong>Explanation:</strong> While the individual pathway components and their disease roles are known separately, the circRNA-mediated regulatory mechanism connecting IL-12/IL-23 to inverse disease outcomes, the specific hub role of circMAN2A1, and the unified framework explaining how the same inflammatory pathway produces opposite disease effects represent genuinely novel contributions synthesizing previously separate findings.</p>            <p><strong>What Already Exists:</strong> IL-12/IL-23 roles in neuroinflammation and AD pathology are documented (Vom Berg et al. 2012). IL-12's function in cancer anti-tumor immunity is well-known. MAN2A1's role in glycosylation and immune response is established (Shi et al. 2020).</p>            <p><strong>What is Novel:</strong> The connection of circRNA-miRNA networks to IL-12/IL-23 pathway regulation as a specific mechanism explaining inverse AD-cancer comorbidity is novel. The identification of circMAN2A1 as a hub regulator linking glycosylation, immune response, and inverse disease outcomes is new. The integration of IL-12/IL-23's opposing effects in AD versus cancer through circRNA-mediated regulation represents a novel mechanistic framework.</p>
        <p><strong>References:</strong> <ul>
    <li>Zhang et al. (2021) Revisiting the Relationship Between Alzheimer's Disease and Cancer With a circRNA Perspective [Novel circRNA-IL-12/IL-23 connection]</li>
    <li>Vom Berg et al. (2012) Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology [IL-12/IL-23 in AD - existing knowledge]</li>
    <li>Shi et al. (2020) Inhibition of MAN2A1 enhances the immune response to anti-PD-L1 in colorectal cancer [MAN2A1 in cancer immunity - existing knowledge]</li>
    <li>Trinchieri (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity [IL-12 biology foundation]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
        </div>
        <div class="section">
            <h2>Theory (Additional Details)</h2>
                        <h3>New Predictions (Likely outcome)</h3>
            <ol>
                <li>Antisense oligonucleotide (ASO) or CRISPR-based depletion of circPICALM, circRTN4, or circMAN2A1 in cell culture models should alter miRNA availability (measurable by qPCR or small RNA-seq) and shift target gene expression in predictable directions based on the circRNA's disease association: depleting AD-downregulated circRNAs should produce cancer-like gene expression patterns</li>
                <li>Peripheral blood circRNA profiling should identify circRNA signatures that correlate with CSF or brain biomarkers of AD pathology (Aβ42, p-tau) and inversely correlate with cancer history, enabling non-invasive risk stratification</li>
                <li>Individuals with hematologic malignancies (AML, JMML) should show particularly strong inverse circRNA signatures compared to solid tumors, as these showed the strongest Spearman correlations (r < -0.5) in the discovery analysis</li>
                <li>Longitudinal circRNA profiling in aging cohorts should reveal trajectories that diverge between individuals who later develop cancer versus AD, with divergence timing predicting time to disease onset</li>
                <li>circRNA signatures should correlate more strongly with Braak staging than with binary AD diagnosis, as observed in the discovery data, making them potentially useful for staging disease progression</li>
            </ol>
            <h3>New Predictions (Unknown outcome/high-entropy)</h3>
            <ol>
                <li>Whether therapeutic modulation of hub circRNAs (circPICALM, circRTN4, circMAN2A1) to intermediate expression levels could minimize combined cancer-neurodegeneration risk is unknown; optimal levels may exist in a narrow therapeutic window requiring precise dosing</li>
                <li>Whether circRNA-based therapeutics (locked nucleic acid inhibitors or circRNA mimics) could selectively modulate disease-relevant miRNA-mRNA networks without substantial off-target effects in non-disease tissues is uncertain given widespread circRNA expression</li>
                <li>The extent to which peripheral blood circRNA manipulation (e.g., via exosome-delivered therapeutic circRNAs) can effectively alter brain circRNA levels and neurodegeneration biomarkers given blood-brain barrier restrictions is unknown</li>
                <li>Whether combining circRNA modulation with other interventions targeting different mechanistic layers (metabolic reprogramming, proteostasis enhancement, immune modulation) creates synergistic protection, additive effects, or unexpected antagonistic interactions is unpredictable without empirical testing</li>
                <li>Whether the inverse circRNA patterns observed in postmortem brain tissue reflect prodromal or causal changes versus late consequences of disease is unresolved; temporal profiling in living subjects would be required</li>
                <li>If circRNA-mediated miRNA sequestration has different stoichiometric requirements in neurons versus cancer cells, the same circRNA level change could have asymmetric effects on the two diseases</li>
            </ol>
            <h3>Negative Experiments</h3>
            <ol>
                <li>If ASO or CRISPR depletion of hub circRNAs (circPICALM, circRTN4, circMAN2A1) does not alter miRNA levels or target mRNA expression in the predicted directions in relevant cell types (neurons, cancer cells), the circRNA sponge mechanism and network predictions would be questioned</li>
                <li>If IL-12/IL-23 pathway modulation (genetic or pharmacological) in well-controlled longitudinal studies does not show inverse effects on AD pathology markers versus tumor progression/immunity, the pathway's role in inverse comorbidity would be challenged</li>
                <li>If peripheral blood circRNA signatures do not correlate with brain tissue circRNA patterns or fail to predict subsequent disease outcomes in prospective cohorts, their biomarker utility and disease relevance would be limited</li>
                <li>If other neurodegenerative diseases beyond protein-aggregation disorders (e.g., multiple sclerosis, stroke) also show inverse circRNA patterns with cancer similar to AD, the mechanistic specificity to protein misfolding would be challenged</li>
                <li>If the single exception circRNA (hsa-miR-29c downregulated in both diseases) represents a more common pattern when more circRNAs are analyzed, the inverse relationship would be less systematic than currently appears</li>
                <li>If Braak staging correlations do not hold in independent cohorts or prospective studies, the disease-stage dependency would be questioned</li>
            </ol>
            <h3>Unaccounted for Evidence</h3>
<ol>
    <li>The molecular mechanisms determining why 12 of 13 circRNAs show inverse patterns while one (hsa-miR-29c) shows same-direction downregulation in both GBM and AD are not explained; structural or regulatory features distinguishing these circRNAs remain unknown <a href="../results/extraction-result-29.html#e29.0" class="evidence-link">[e29.0]</a> <a href="../results/extraction-result-34.html#e34.0" class="evidence-link">[e34.0]</a> </li>
    <li>Tissue-specific circRNA expression differences between brain regions (cortex analyzed in AD studies) and peripheral tissues (blood, which would be used for biomarker applications) may limit translatability of findings <a href="../results/extraction-result-34.html#e34.0" class="evidence-link">[e34.0]</a> </li>
    <li>The relative quantitative contribution of circRNA-miRNA sponging versus other mechanisms (direct protein interactions, transcriptional regulation) to inverse disease patterns is not quantified <a href="../results/extraction-result-34.html#e34.0" class="evidence-link">[e34.0]</a> </li>
    <li>Cell-type-specific circRNA expression and function within heterogeneous brain tissue (neurons vs. glia) and tumor microenvironment is not resolved by bulk tissue analysis <a href="../results/extraction-result-34.html#e34.0" class="evidence-link">[e34.0]</a> </li>
    <li>Temporal dynamics of circRNA changes during disease progression (which changes are early/causal vs. late/consequential) are not established by cross-sectional postmortem analysis <a href="../results/extraction-result-34.html#e34.0" class="evidence-link">[e34.0]</a> </li>
    <li>Stoichiometric requirements for effective miRNA sponging (how many circRNA molecules needed per miRNA to achieve functional sequestration) are not quantified in this analysis <a href="../results/extraction-result-34.html#e34.0" class="evidence-link">[e34.0]</a> </li>
    <li>Species differences in circRNA sequences, expression, and function between mouse models (where IL-12/IL-23 manipulation was tested) and humans may affect translatability <a href="../results/extraction-result-34.html#e34.0" class="evidence-link">[e34.0]</a> </li>
</ol>        </div>        <div style="height: 30px;"></div>
    </div>
</body>
</html>